Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases — kidney, liver and lung fibrosis — the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
A new Northwestern Medicine study has newly identified a trigger of some fibrotic diseases and an experimental compound to treat it.
Fibrosis — a progressive scarring and hardening of internal organs — is estimated to cause 35 to 40 percent of deaths in the world. Fibrotic diseases include diabetic kidney fibrosis, alcoholic liver cirrhosis, hepatitis C, pulmonary fibrosis and nonalcoholic fatty liver disease, which may lead to fibrosis of the liver, the leading cause of liver transplant.
In one subset of human fibrosis cells, scientists discovered a delinquent gang of molecules that continually shouted at an immune receptor — the antennae on the cell — to produce scar tissue instead of quieting down and allowing the scar tissue to go back to sleep.
Scientists collaborated with a University of Colorado researcher who used crystallography and computer modeling to predict a molecule that could block the receptor that leads to the uncontrolled scarring. When they tested the molecule, T53, in three different mouse models of fibrosis, the abnormality was significantly reversed.
“Our study opens a new door into fibrosis by looking at it as an aberrant innate immune response and suggesting a novel approach to treat it,” said senior author Dr. John Varga, director of the Northwestern Scleroderma Program and the John and Nancy Hughes Distinguished Professor of Rheumatology at Northwestern University Feinberg School of Medicine.
The paper was published July 12 in the Journal of Clinical Investigation Insight.
“The leading cause of liver failure in western world is obesity and that’s because of liver fibrosis,” Varga said. “In the U.S., many of these diseases are lifestyle or age dependent. As we get fatter or older, they get worse.”
Most fibrotic disease likely begins as normal repair of an injury, scientists said. “But if the immune system produces too much of an initial scar, it can’t go back to normal,” Varga said. “You have an unhealed scar that keeps growing and can wipe out the entire organ.”
Not everyone’s fibrosis is caused by the same abnormality, Varga said. If the compound, T53, is eventually developed into an approved drug, it would be targeted to patients with the specific genetic signature identified in the study.
“There is an emerging direction for treating fibrosis with precision medicine,” said first author Swati Bhattacharyya, research associate professor of medicine in rheumatology and scientific director of the Scleroderma Research Laboratory at Feinberg. “Some people live with fibrotic disease for 30 years while others die in two years. We need to identify the rapid progressors from the slow progressors. That’s where precision medicine becomes really critical.”
“The results of this study are encouraging,” Varga said. “We are not saying this compound is ready to be a drug. It’s an initial compound that would need to be developed and tweaked. It would need significant funding to go to the next step.”
Learn more: Why internal scars won’t stop growing
The Latest on: Fibrosis
via Google News
The Latest on: Fibrosis
- Calithera Biosciences’ CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the North American Cystic Fibrosis 2020 Virtual Conferenceon October 8, 2020 at 11:42 am
The randomized, double-blind, placebo-controlled, multiple ascending dose-escalation study (NCT04279769) is exploring CB-280 versus placebo in adults with cystic fibrosis and chronic infection ...
- NJ Devils Draft 13-Year-Old Fan Fighting Cystic Fibrosis, Welcome To Our Family!on October 8, 2020 at 11:32 am
The New Jersey Devils just made a dream come true for one of their biggest fans ... by selecting a 13-year-old with an honorary draft pick!!
- Seibels Marks $500K Milestone in Fight Against Cystic Fibrosison October 8, 2020 at 11:16 am
Seibels marked a significant milestone as Chairman & CEO, Rex Huggins, announced that the Company hit the $500,000 mark in fundraising for the Cystic Fibrosis Foundation (CFF). That number reflects ...
- Treating cystic fibrosis with mRNA therapy or CRISPRon October 8, 2020 at 10:26 am
The potential for treating cystic fibrosis (CF) using mRNA therapies or CRISPR gene editing is possible regardless of the causative mutation. CF clinical trials showing that a genotype-agnostic gene t ...
- Outlook on the 2020 Liver Fibrosis Industry - Clinical Trial Pipeline Highlights - ResearchAndMarkets.comon October 8, 2020 at 7:23 am
The "Global Liver Fibrosis Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.
- Using mRNA therapies or CRISPR gene editing to treat cystic fibrosison October 7, 2020 at 5:01 pm
The potential for treating cystic fibrosis (CF) using mRNA therapies or CRISPR gene editing is possible regardless of the causative mutation. CF clinical trials showing that a genotype-agnostic gene ...
- Fibrosis biotech Galecto files for a $100 million IPOon October 7, 2020 at 4:53 pm
G alecto, a Phase 2 biotech developing therapeutics for fibrosis and fibrotic related diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Galecto's ...
- Roche targets cystic fibrosis with deal for TMEM16A potentiatoron October 7, 2020 at 5:10 am
Roche has bought a phase 1 pan-genotype cystic fibrosis program from Enterprise Therapeutics. The deal, which is worth £75 million ($97 million) upfront to Enterprise’s shareholders, gives Roche a ...
- AXGT Reports Parkinson's Trial Data, CRBP Plunges As Cystic Fibrosis Study Fails, GMDA On Trackon October 7, 2020 at 12:45 am
Today's Daily Dose brings you news about Axovant Gene's Parkinson's disease trial results, Corbus Pharma's cystic fibrosis trial data, Gamda's progress with Omidubicel, an investigational advanced ...
via Bing News